[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100576390","maternal-abdominal-morphology-assessment-100576390",false,"NCT06784674","Maternal Abdominal Morphology Assessment","Diabetes Prediction During Pregnancy Using Pancreas MRI","MAMA","Inclusion Criteria:\n\n* Pregnant women, with a singleton gestation\n* Age 18 - 54 years at screening\n* Gestational age \\\u003C 14 weeks\n* Willing to commit to 1 year postpartum follow up\n* Planning to remain in geographical vicinity of Austin for 1 year after delivery\n\nExclusion Criteria:\n\n* Presence of any mechanically or magnetically activated implants\n* Claustrophobia\n* Other contraindication for MRI\n* BMI ≥ 38.0 or maximum width less than 48 cm (necessary to fit within the MRI field of view)",true,"FEMALE","18 Years","54 Years",{"count":22,"type":23},87,"ESTIMATED","OBSERVATIONAL","Previous studies have shown that pancreas size tends to be smaller in individuals with diabetes compared to those without diabetes. The investigators have recently found that pancreas size increases during pregnancy. The MAMA study aims to examine changes in the pancreas that occur during pregnancy, in both pregnant mothers and their babies, and find out how they are affected by maternal diabetes.\n\nThe MAMA study is a prospective cohort study that will follow women and their babies through pregnancy and one year postpartum. Women aged 18-54, who are under 14 weeks pregnant are being recruited to participate in the MAMA study.",[27,28,29,30],"Pregnancy Related","Infant Development","Pancreas","Diabetes",[32,29,30],"Pregnancy","RECRUITING","2025-10-20",{"date":36,"type":37},"2025-10-22","ACTUAL",{"date":39,"type":37},"2025-05-06",{"date":41,"type":23},"2031-12",{"name":43,"class":44},"University of Texas at Austin","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":19,"maxAge":54,"enrollmentInfo":4,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":70,"locationsCount":45},"100192898","magnetic-resonance-guided-high-intensity-focused-ultrasound-treatment-of-locally-advanced-pancreatic-cancer-100192898","NCT01786850","Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer","Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer: Phase II Study for Pain Palliation and Local Tumor Control","Inclusion Criteria:\n\n* biopsy proven unresectable pancreatic adenocarcinoma;\n* unable or not willing to undergo chemo-radiation therapy\n* Celiac plexus alcoholization failed to control pain symptoms\n\nExclusion Criteria:\n\n* contraindication to MR or general anesthesia","ALL","90 Years","EXPANDED_ACCESS","Patients with unresectable pancreatic cancer in most of cases cannot benefit from percutaneous ablation modalities, due to high risk of procedure-related complications. Ultrasound-guided high intensity focused ultrasound (HIFU) ablation has been introduced as a feasible treatment option in these patients. However, in other anatomical regions US-guided HIFU has been replaced by the more accurate MR-guided focused ultrasound (MRgFUS) ablation, but the applicability of this latter technique to the treatment of pancreatic cancer is still unexplored. The aim of this study is to explore feasibility and clinical performance of MRgFUS ablation of unresectable pancreatic cancer. Two are the main end-points: Pain palliation and local tumor control.\n\nAs compared to conventional US-guided HIFU, MRgFUS could represent a more accurate, non-invasive ablation modality even for unresectable pancreatic cancer although, to date, no cases of pancreatic MRgFUS ablation have been reported.",[29,58,59,60],"Cancer","Locally Advanced Pancreatic Cancer","Non-invasive Treatment",[62,63,64,65],"Locally advanced Pancreatic Cancer","Noninvasive treatment","High Intensity focused ultrasound","Magnetic Resonance","AVAILABLE","2014-06-17",{"date":69,"type":23},"2014-06-18",{"name":71,"class":44},"University of Roma La Sapienza"]